Maria Mironova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Maria Mironova has a total of 82 co-authors. Here are the top co-authors by number of shared publications:
- Theo Heller
Translational Hepatology Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA
10 shared publications - Harish Gopalakrishna
Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA
7 shared publications - Christopher Koh
Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA
6 shared publications - David E. Kleiner
Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, USA
4 shared publications - Rohit Loomba
MASLD Research Center, Division of Gastroenterology and Hepatology, University of California, San Diego, La Jolla, CA, 92037
4 shared publications - Yaron Rotman
Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA
2 shared publications
Latest Publications
- 2 November 2026
- Published by Wolters Kluwer Health in Hepatology
MRI-based biomarkers for risk stratification and assessment of treatment response in Metabolic dysfunction-associated Steatotic liver disease
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects up to 38% of the population globally. Liver biopsy, the historical reference standard, is invasive, subject to sampling error and not scalable. MRI-based biomarkers provide non-invasive, quantitative whole liver assessment. MRI proton density fat fraction (MRI-PDFF) is the most accurate noninvasive measure of steatosis (thresholds of 6.4%, 17.4% and 22.1% for grades ≥1, ≥2 and 3), and a ≥30% relative reduction is associated with histologic response. Liver stiffness by magnetic resonance elastography (MRE-LS) is the most accurate imaging biomarker for fibrosis: MRE-LS of 3.1-4.4 kPa corresponds to F2-F3 and ≥5 kPa to cirrhosis, and each 1-kPa increase is associated with a 43% higher risk of hepatic decompensation. Iron-corrected T1 is a sensitive but nonspecific marker of disease activity whose prognostic value requires further study. Composite scores, MAST, MEFIB, and MASH Resolution Index, combine imaging and blood tests for advanced fibrosis diagnosis and response assessment. MRE is cost-effective compared with vibration-controlled transient elastography for detecting advanced fibrosis. Artificial intelligence may broaden access by automating analysis and enabling PDFF from routine MRI. We review the evidence supporting these biomarkers for diagnosis, prognosis and regulatory use, and their role in clinical trials and in treatment decisions for approved MASH therapies.
- 2 November 2026
- Published by Wolters Kluwer Health in Hepatology
MRI-based biomarkers for risk stratification and assessment of treatment response in Metabolic dysfunction-associated Steatotic liver disease
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects up to 38% of the population globally. Liver biopsy, the historical reference standard, is invasive, subject to sampling error and not scalable. MRI-based biomarkers provide non-invasive, quantitative whole liver assessment. MRI proton density fat fraction (MRI-PDFF) is the most accurate noninvasive measure of steatosis (thresholds of 6.4%, 17.4% and 22.1% for grades ≥1, ≥2 and 3), and a ≥30% relative reduction is associated with histologic response. Liver stiffness by magnetic resonance elastography (MRE-LS) is the most accurate imaging biomarker for fibrosis: MRE-LS of 3.1-4.4 kPa corresponds to F2-F3 and ≥5 kPa to cirrhosis, and each 1-kPa increase is associated with a 43% higher risk of hepatic decompensation. Iron-corrected T1 is a sensitive but nonspecific marker of disease activity whose prognostic value requires further study. Composite scores, MAST, MEFIB, and MASH Resolution Index, combine imaging and blood tests for advanced fibrosis diagnosis and response assessment. MRE is cost-effective compared with vibration-controlled transient elastography for detecting advanced fibrosis. Artificial intelligence may broaden access by automating analysis and enabling PDFF from routine MRI. We review the evidence supporting these biomarkers for diagnosis, prognosis and regulatory use, and their role in clinical trials and in treatment decisions for approved MASH therapies.
- Open Access
- 29 September 2026
- Published by Wiley in Liver International
- Vol. 46 (10) , e70873
Distinct Plasma Proteomic Signatures Distinguish MASLD From Non‐Steatotic Individuals but Not From MetALD
Background and Aims: Metabolic dysfunction associated steatotic liver disease (MASLD) is the most prevalent liver disease, yet accurate early detection remains challenging. A particular diagnostic obstacle is distinguishing MASLD from metabolic dysfunction and alcohol‐related liver disease (MetALD), currently defined using clinically informed moderate alcohol consumption thresholds without biological validation. This study aimed to identify and externally validate plasma proteomic signatures associated with MASLD and assess whether proteomic profiles support a molecular distinction between MASLD and MetALD as currently defined. Methods: We analysed plasma proteomic profiles using OLINK data from UK Biobank (UKB) participants with liver MRI. MASLD was defined as MRI‐PDFF ≥ 5% and metabolic dysfunction ( n = 165), MetALD ( n = 46) as MASLD with additional moderate alcohol intake and controls as PDFF < 5% ( n = 741). Results: Compared to controls, participants with MASLD showed 17 upregulated and 3 downregulated proteins after Bonferroni correction (adjusted p < 0.05). Among upregulated proteins, leptin (LEP), fatty acid‐binding protein, liver (FABP1) and aminoacylase1 (ACY1) and among downregulated, insulin‐like growth factor‐binding protein 1 (IGFBP1) were externally validated in an independent cohort (clinicaltrials.gov NCT02520609, n = 47). Individuals with MetALD showed no significant proteomic distinction from MASLD. Although the small MetALD sample size may have limited detection of differences, direct differential expression analysis did not identify statistically significant differences between MASLD and MetALD under the current clinical thresholds. Conclusions: MASLD was associated with a reproducible plasma proteomic signature enriched for proteins involved in lipid metabolism, inflammation and hormonal regulation. We did not identify a clear proteomic distinction between MASLD and MetALD under the current alcohol thresholds. However, this finding should be interpreted considering limited power and potential alcohol‐exposure misclassification.
- 29 September 2026
- Published by Wiley in Liver International
- Vol. 46 (10) , e70873
Open AccessDistinct Plasma Proteomic Signatures Distinguish MASLD From Non‐Steatotic Individuals but Not From MetALD
Background and Aims: Metabolic dysfunction associated steatotic liver disease (MASLD) is the most prevalent liver disease, yet accurate early detection remains challenging. A particular diagnostic obstacle is distinguishing MASLD from metabolic dysfunction and alcohol‐related liver disease (MetALD), currently defined using clinically informed moderate alcohol consumption thresholds without biological validation. This study aimed to identify and externally validate plasma proteomic signatures associated with MASLD and assess whether proteomic profiles support a molecular distinction between MASLD and MetALD as currently defined. Methods: We analysed plasma proteomic profiles using OLINK data from UK Biobank (UKB) participants with liver MRI. MASLD was defined as MRI‐PDFF ≥ 5% and metabolic dysfunction ( n = 165), MetALD ( n = 46) as MASLD with additional moderate alcohol intake and controls as PDFF < 5% ( n = 741). Results: Compared to controls, participants with MASLD showed 17 upregulated and 3 downregulated proteins after Bonferroni correction (adjusted p < 0.05). Among upregulated proteins, leptin (LEP), fatty acid‐binding protein, liver (FABP1) and aminoacylase1 (ACY1) and among downregulated, insulin‐like growth factor‐binding protein 1 (IGFBP1) were externally validated in an independent cohort (clinicaltrials.gov NCT02520609, n = 47). Individuals with MetALD showed no significant proteomic distinction from MASLD. Although the small MetALD sample size may have limited detection of differences, direct differential expression analysis did not identify statistically significant differences between MASLD and MetALD under the current clinical thresholds. Conclusions: MASLD was associated with a reproducible plasma proteomic signature enriched for proteins involved in lipid metabolism, inflammation and hormonal regulation. We did not identify a clear proteomic distinction between MASLD and MetALD under the current alcohol thresholds. However, this finding should be interpreted considering limited power and potential alcohol‐exposure misclassification.
- Open Access
- 24 August 2026
- Published by Wiley in Alimentary Pharmacology & Therapeutics
Editorial: Clinically Meaningful Cut‐Points for ELF in Fibrosis Risk Stratification in MASLD
- 24 August 2026
- Published by Wiley in Alimentary Pharmacology & Therapeutics
Open AccessEditorial: Clinically Meaningful Cut‐Points for ELF in Fibrosis Risk Stratification in MASLD
- 29 July 2026
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 64 (7) , 919-929
Clinical Trial: Phase 3 Trial of Resmetirom Versus Placebo in Metabolic Dysfunction‐Associated Steatohepatitis—Reanalysis of Fibrosis Stage 2–3 Subset
Background: Resmetirom is an oral thyroid hormone receptor beta agonist clinically used to treat metabolic dysfunction‐associated steatohepatitis (MASH) among adults with stage F2 or F3 fibrosis. Aims: Because the pivotal, 52‐week, randomized, controlled, phase 3 MAESTRO‐NASH trial (once‐daily oral resmetirom 80 or 100 mg or placebo) included patients with F1, F2, or F3 fibrosis, we conducted a post hoc analysis aimed at assessing treatment response in the subset of patients with stages F2 and F3 fibrosis, consistent with the approved label population. Methods: Co‐primary end points were MASH resolution (hepatocellular ballooning score 0, lobular inflammation score ≤ 1, and ≥ 2‐point nonalcoholic fatty liver disease activity score [NAS] reduction from baseline) with no fibrosis worsening, and ≥ 1‐stage fibrosis improvement with no NAS worsening at Week 52. Results: Among 917 patients with F2 or F3 fibrosis, metabolic risk factor prevalence was high (hypertension, 78.0%; dyslipidemia, 71.1%; type 2 diabetes, 67.0%). MASH resolution was achieved by 25.7% in the 80‐mg group, 29.9% in the 100‐mg group, and 9.5% in the placebo group ( p < 0.0001 for both comparisons with placebo). Respective percentages with fibrosis improvement were 26.5%, 28.9%, and 17.3% ( p < 0.01 for both comparisons). From baseline to Week 24, low‐density lipoprotein cholesterol decreased by 11.7% and 13.7% in the 80‐ and 100‐mg resmetirom groups, respectively, and increased by 2.3% with placebo ( p < 0.0001 for both comparisons). No new safety signals emerged. Conclusion: Results among patients with F2 and F3 fibrosis were consistent with the primary MAESTRO‐NASH analysis population, demonstrating efficacy and safety of resmetirom after 52 weeks.
- 29 July 2026
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 64 (7) , 919-929
Clinical Trial: Phase 3 Trial of Resmetirom Versus Placebo in Metabolic Dysfunction‐Associated Steatohepatitis—Reanalysis of Fibrosis Stage 2–3 Subset
Background: Resmetirom is an oral thyroid hormone receptor beta agonist clinically used to treat metabolic dysfunction‐associated steatohepatitis (MASH) among adults with stage F2 or F3 fibrosis. Aims: Because the pivotal, 52‐week, randomized, controlled, phase 3 MAESTRO‐NASH trial (once‐daily oral resmetirom 80 or 100 mg or placebo) included patients with F1, F2, or F3 fibrosis, we conducted a post hoc analysis aimed at assessing treatment response in the subset of patients with stages F2 and F3 fibrosis, consistent with the approved label population. Methods: Co‐primary end points were MASH resolution (hepatocellular ballooning score 0, lobular inflammation score ≤ 1, and ≥ 2‐point nonalcoholic fatty liver disease activity score [NAS] reduction from baseline) with no fibrosis worsening, and ≥ 1‐stage fibrosis improvement with no NAS worsening at Week 52. Results: Among 917 patients with F2 or F3 fibrosis, metabolic risk factor prevalence was high (hypertension, 78.0%; dyslipidemia, 71.1%; type 2 diabetes, 67.0%). MASH resolution was achieved by 25.7% in the 80‐mg group, 29.9% in the 100‐mg group, and 9.5% in the placebo group ( p < 0.0001 for both comparisons with placebo). Respective percentages with fibrosis improvement were 26.5%, 28.9%, and 17.3% ( p < 0.01 for both comparisons). From baseline to Week 24, low‐density lipoprotein cholesterol decreased by 11.7% and 13.7% in the 80‐ and 100‐mg resmetirom groups, respectively, and increased by 2.3% with placebo ( p < 0.0001 for both comparisons). No new safety signals emerged. Conclusion: Results among patients with F2 and F3 fibrosis were consistent with the primary MAESTRO‐NASH analysis population, demonstrating efficacy and safety of resmetirom after 52 weeks.
- 24 June 2026
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
PREVALENCE AND RISK FACTORS ASSOCIATED WITH MASLD AND ADVANCED FIBROSIS AMONG OVERWEIGHT INDIVIDUALS: IMPLICATIONS FOR SCREENING GUIDELINES.
BACKGROUND AND AIMS: Current AASLD guidelines recommend evaluation for fibrosis in diabetes or medically complicated obesity, and screening for metabolic dysfunction-associated steatotic liver disease (MASLD) in people with cardiometabolic risk factors (CMRFs), but they do not define which metabolic and other risk factors warrant screening in overweight individuals. We aimed to identify risk factors that should prompt liver disease assessment in overweight individuals. METHODS: This is a cross-sectional analysis of community-dwelling adults (aged 40-75) residing in Southern California and enrolled in a prospective study. MASLD was defined as liver fat content ≥5% measured by MRI-PDFF in the absence of other liver diseases and with no or mild alcohol use; advanced fibrosis was defined as ≥3.63 kPa measured by MRE. RESULTS: Among 220 overweight individuals (mean age 56.8 ± 9.6 years, 50.9% male), 52% had MASLD, of whom 7% had advanced fibrosis. Hypertriglyceridemia was the strongest independent MASLD predictor (OR 3.11, 95% CI 1.42–6.81, p=0.005), followed by hypertension (OR 2.51, 95% CI 1.21–5.23, p=0.014). For advanced fibrosis, Hispanic ethnicity, diabetes and low HDL were significant predictors. Notably, 61% of overweight individuals with MASLD did not have diabetes. Targeting overweight individuals with any CMRF for evaluation would identify 93.9% of MASLD cases, compared to only 40.5% when using diabetes alone as the screening trigger. CONCLUSION: Current guidelines should be expanded to include overweight individuals with any cardiometabolic risk factor, not just diabetes, as candidates for FIB-4 assessment. Fibrosis surveillance among overweight individuals should prioritize those with diabetes, as recommended by current guidelines, as well as people of Hispanic ethnicity.
- 24 June 2026
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
PREVALENCE AND RISK FACTORS ASSOCIATED WITH MASLD AND ADVANCED FIBROSIS AMONG OVERWEIGHT INDIVIDUALS: IMPLICATIONS FOR SCREENING GUIDELINES.
BACKGROUND AND AIMS: Current AASLD guidelines recommend evaluation for fibrosis in diabetes or medically complicated obesity, and screening for metabolic dysfunction-associated steatotic liver disease (MASLD) in people with cardiometabolic risk factors (CMRFs), but they do not define which metabolic and other risk factors warrant screening in overweight individuals. We aimed to identify risk factors that should prompt liver disease assessment in overweight individuals. METHODS: This is a cross-sectional analysis of community-dwelling adults (aged 40-75) residing in Southern California and enrolled in a prospective study. MASLD was defined as liver fat content ≥5% measured by MRI-PDFF in the absence of other liver diseases and with no or mild alcohol use; advanced fibrosis was defined as ≥3.63 kPa measured by MRE. RESULTS: Among 220 overweight individuals (mean age 56.8 ± 9.6 years, 50.9% male), 52% had MASLD, of whom 7% had advanced fibrosis. Hypertriglyceridemia was the strongest independent MASLD predictor (OR 3.11, 95% CI 1.42–6.81, p=0.005), followed by hypertension (OR 2.51, 95% CI 1.21–5.23, p=0.014). For advanced fibrosis, Hispanic ethnicity, diabetes and low HDL were significant predictors. Notably, 61% of overweight individuals with MASLD did not have diabetes. Targeting overweight individuals with any CMRF for evaluation would identify 93.9% of MASLD cases, compared to only 40.5% when using diabetes alone as the screening trigger. CONCLUSION: Current guidelines should be expanded to include overweight individuals with any cardiometabolic risk factor, not just diabetes, as candidates for FIB-4 assessment. Fibrosis surveillance among overweight individuals should prioritize those with diabetes, as recommended by current guidelines, as well as people of Hispanic ethnicity.
- Open Access
- 1 January 2026
- Published by Wiley in Case Reports in Hepatology
- Vol. 2026 (1)
Exceptionally Long Recurrence‐Free Survival in a Male Patient With Fibrolamellar Hepatocellular Carcinoma
Fibrolamellar hepatocellular carcinoma (FLHCC) accounts for less than 1% of all primary liver cancers. Due to an absence of known risk factors, most individuals are diagnosed at advanced stages of disease. Subsequently, these tumors carry a 30%–50% mortality rate and a 33%–100% recurrence rate in those treated with curative intent. Here, we describe an incidental discovery of an FLHCC tumor in a young male patient, who following surgical resection has remained recurrence free for over 11 years. This exceptionally long recurrence‐free survival highlights the advantage of early‐stage detection, the benefit of complete tumor resection, and further underscores the importance of regular postresection cancer surveillance.
- 1 January 2026
- Published by Wiley in Case Reports in Hepatology
- Vol. 2026 (1)
Open AccessExceptionally Long Recurrence‐Free Survival in a Male Patient With Fibrolamellar Hepatocellular Carcinoma
Fibrolamellar hepatocellular carcinoma (FLHCC) accounts for less than 1% of all primary liver cancers. Due to an absence of known risk factors, most individuals are diagnosed at advanced stages of disease. Subsequently, these tumors carry a 30%–50% mortality rate and a 33%–100% recurrence rate in those treated with curative intent. Here, we describe an incidental discovery of an FLHCC tumor in a young male patient, who following surgical resection has remained recurrence free for over 11 years. This exceptionally long recurrence‐free survival highlights the advantage of early‐stage detection, the benefit of complete tumor resection, and further underscores the importance of regular postresection cancer surveillance.
- 27 November 2025
- Published by Wolters Kluwer Health in Clinical and Translational Gastroenterology
- Vol. 17 (2) , e00956
Noninvasive Markers Associated With Portal Hypertension and Varices in Patients With Noncirrhotic Portal Hypertension
INTRODUCTION: Noncirrhotic portal hypertension (NCPH) refers to a diverse group of disorders that affects the hepatic portosinusoidal vascular system resulting in portal hypertension (PH). Unlike cirrhosis, there are no noninvasive criteria to diagnose PH and varices in NCPH. METHODS: A prospective cohort of patients with NCPH who had transjugular liver biopsy, liver stiffness (LSM) measured using transient elastography, and laboratory and imaging data were included. PH was defined by the presence of one among the following—varices on endoscopy, portosystemic collaterals, or ascites on imaging. Logistic regression was used to identify predictors. The classification tree approach was used to identify cutoff values for the stepwise decision model. RESULTS: Of the 59 patients, 41 (69%) had PH and 36 (62%) had varices. LSM was higher in patients with PH (11.5 kPa vs 5.7 kPa, P < 0.01) and varices (12 kPa vs 5.9 kPa, P < 0.01). Platelet count was lower in patients with PH (79 vs 218 × 10 9 /L, P < 0.01) and varices (75 vs 209 × 10 9 /L, P < 0.01). Multivariate analysis combining LSM and platelet count predicts PH (area under receiver operating characteristic 96% [91%–99%]) and varices (area under receiver operating characteristic 92% [85%–99%]). A stepwise model combining platelet 140 × 10 9 /L and LSM 7 kPa performed with a sensitivity of 100%, negative predictive value of 100%, and accuracy of 90% to detect PH. The same model performed with sensitivity of 100%, negative predictive value of 100%, and accuracy of 81% to detect varices. DISCUSSION: Noninvasive model combining LSM with platelet count can aid in identifying NCPH patients with PH and varices. However, this model requires validation in an independent cohort.
- 27 November 2025
- Published by Wolters Kluwer Health in Clinical and Translational Gastroenterology
- Vol. 17 (2) , e00956
Noninvasive Markers Associated With Portal Hypertension and Varices in Patients With Noncirrhotic Portal Hypertension
INTRODUCTION: Noncirrhotic portal hypertension (NCPH) refers to a diverse group of disorders that affects the hepatic portosinusoidal vascular system resulting in portal hypertension (PH). Unlike cirrhosis, there are no noninvasive criteria to diagnose PH and varices in NCPH. METHODS: A prospective cohort of patients with NCPH who had transjugular liver biopsy, liver stiffness (LSM) measured using transient elastography, and laboratory and imaging data were included. PH was defined by the presence of one among the following—varices on endoscopy, portosystemic collaterals, or ascites on imaging. Logistic regression was used to identify predictors. The classification tree approach was used to identify cutoff values for the stepwise decision model. RESULTS: Of the 59 patients, 41 (69%) had PH and 36 (62%) had varices. LSM was higher in patients with PH (11.5 kPa vs 5.7 kPa, P < 0.01) and varices (12 kPa vs 5.9 kPa, P < 0.01). Platelet count was lower in patients with PH (79 vs 218 × 10 9 /L, P < 0.01) and varices (75 vs 209 × 10 9 /L, P < 0.01). Multivariate analysis combining LSM and platelet count predicts PH (area under receiver operating characteristic 96% [91%–99%]) and varices (area under receiver operating characteristic 92% [85%–99%]). A stepwise model combining platelet 140 × 10 9 /L and LSM 7 kPa performed with a sensitivity of 100%, negative predictive value of 100%, and accuracy of 90% to detect PH. The same model performed with sensitivity of 100%, negative predictive value of 100%, and accuracy of 81% to detect varices. DISCUSSION: Noninvasive model combining LSM with platelet count can aid in identifying NCPH patients with PH and varices. However, this model requires validation in an independent cohort.
- 7 October 2025
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 111 (4) , 1057-1065
Serum Proteomics of Insulin Resistance Disorders Distinguish MASLD From Lipodystrophy and Insulin Receptor Defects
Background and Aims: Metabolic dysfunction-associated steatotic liver disease (MASLD) is linked to obesity, metabolic syndrome, and insulin resistance (IR). In IR associated with obesity or lipodystrophy (LD), caused by missing adipose tissue, hyperinsulinemia stimulates hepatic lipogenesis, causing steatotic liver disease (SLD). In contrast, insulin receptor pathogenic variants (INSR), despite hyperinsulinemia and IR, do not promote hepatic lipogenesis and steatosis. We aimed to understand SLD pathophysiology by comparing serum proteomic signatures of MASLD, LD, and INSR. Methods: Single-center study of fasting serum proteome using SomaScan assay in 30 LD, 29 INSR, and 16 people with MASLD. Key targets were assessed in the hepatic transcriptome of patients with MASLD (n = 19) and in HepG2 cells. Results: Of 6412 proteins, 567 differed between at least 2 groups. The proteome profiles clearly separated INSR from the other groups, whereas MASLD and LD displayed similarity, primarily in proteins involved in metabolism, liver injury, and fibrosis. Several proteins were uniquely elevated in INSR and LD compared to MASLD, particularly Factor IX and liver-expressed antimicrobial peptide 2. Serum levels of Factor IX and liver-expressed antimicrobial peptide 2 correlated with their hepatic expression, with in vitro expression unaffected by leptin, insulin, or glucose treatment. Conclusion: This first comparative proteomics study identified shared and unique pathways in IR disorders. MASLD and LD share features, suggesting similar drivers of liver disease progression. Key liver-derived proteins differ between MASLD, INSR, and LD because of unique disorder features. We demonstrate the utility of proteomics and rare disorder studies in interrogating pathogenesis of common disorders like MASLD.
- 7 October 2025
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 111 (4) , 1057-1065
Serum Proteomics of Insulin Resistance Disorders Distinguish MASLD From Lipodystrophy and Insulin Receptor Defects
Background and Aims: Metabolic dysfunction-associated steatotic liver disease (MASLD) is linked to obesity, metabolic syndrome, and insulin resistance (IR). In IR associated with obesity or lipodystrophy (LD), caused by missing adipose tissue, hyperinsulinemia stimulates hepatic lipogenesis, causing steatotic liver disease (SLD). In contrast, insulin receptor pathogenic variants (INSR), despite hyperinsulinemia and IR, do not promote hepatic lipogenesis and steatosis. We aimed to understand SLD pathophysiology by comparing serum proteomic signatures of MASLD, LD, and INSR. Methods: Single-center study of fasting serum proteome using SomaScan assay in 30 LD, 29 INSR, and 16 people with MASLD. Key targets were assessed in the hepatic transcriptome of patients with MASLD (n = 19) and in HepG2 cells. Results: Of 6412 proteins, 567 differed between at least 2 groups. The proteome profiles clearly separated INSR from the other groups, whereas MASLD and LD displayed similarity, primarily in proteins involved in metabolism, liver injury, and fibrosis. Several proteins were uniquely elevated in INSR and LD compared to MASLD, particularly Factor IX and liver-expressed antimicrobial peptide 2. Serum levels of Factor IX and liver-expressed antimicrobial peptide 2 correlated with their hepatic expression, with in vitro expression unaffected by leptin, insulin, or glucose treatment. Conclusion: This first comparative proteomics study identified shared and unique pathways in IR disorders. MASLD and LD share features, suggesting similar drivers of liver disease progression. Key liver-derived proteins differ between MASLD, INSR, and LD because of unique disorder features. We demonstrate the utility of proteomics and rare disorder studies in interrogating pathogenesis of common disorders like MASLD.
- 3 September 2025
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 71 (2) , 643-650
Real World Performance of the Model for End-Stage Liver Disease Score Across Different Races and Ethnicities
Background and Aims The MELD score assesses liver disease severity and guides liver allocation in the United States. This study aims to address the knowledge gap regarding potential disparities in the performance of MELD-Na and MELD 3.0 scores across races and ethnicities. Methods A retrospective cohort study of Asian, White, African American, and Hispanic patients with cirrhosis from MIMIC-IV (Beth Israel Deaconess Medical Center) and Emory University databases. The performance of the MELD scores in predicting a composite outcome of death or liver transplant (LT) during the hospital stay or within 90 days was analyzed using AUROC for discrimination, and calibration curves for calibration. Results A total of 4,306 patients with cirrhosis from MIMIC-IV and 5801 patients from Emory were included. Across both datasets, no significant differences were found in the discriminative ability of both scores to predict in-hospital death or LT across races and ethnicities (p > 0.05). A small group of Asian patients influenced score performance differences at 90 days in MIMIC-IV. Calibration plots showed both scores tend to overpredict outcomes at higher values, particularly MELD-Na in MIMIC-IV among African Americans. Conclusions Both scores demonstrated consistent discriminative ability across major ethnic/racial groups. Both scores predicted outcomes better in Emory, a high-volume LT center, than in MIMIC-IV, suggesting site-specific differences and the Emory cohort’s closer resemblance to populations used for MELD derivation. These findings suggest disparities in cirrhosis care may relate to socioeconomic factors rather than score performance.
- 3 September 2025
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 71 (2) , 643-650
Real World Performance of the Model for End-Stage Liver Disease Score Across Different Races and Ethnicities
Background and Aims The MELD score assesses liver disease severity and guides liver allocation in the United States. This study aims to address the knowledge gap regarding potential disparities in the performance of MELD-Na and MELD 3.0 scores across races and ethnicities. Methods A retrospective cohort study of Asian, White, African American, and Hispanic patients with cirrhosis from MIMIC-IV (Beth Israel Deaconess Medical Center) and Emory University databases. The performance of the MELD scores in predicting a composite outcome of death or liver transplant (LT) during the hospital stay or within 90 days was analyzed using AUROC for discrimination, and calibration curves for calibration. Results A total of 4,306 patients with cirrhosis from MIMIC-IV and 5801 patients from Emory were included. Across both datasets, no significant differences were found in the discriminative ability of both scores to predict in-hospital death or LT across races and ethnicities (p > 0.05). A small group of Asian patients influenced score performance differences at 90 days in MIMIC-IV. Calibration plots showed both scores tend to overpredict outcomes at higher values, particularly MELD-Na in MIMIC-IV among African Americans. Conclusions Both scores demonstrated consistent discriminative ability across major ethnic/racial groups. Both scores predicted outcomes better in Emory, a high-volume LT center, than in MIMIC-IV, suggesting site-specific differences and the Emory cohort’s closer resemblance to populations used for MELD derivation. These findings suggest disparities in cirrhosis care may relate to socioeconomic factors rather than score performance.
- 30 April 2025
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 120 (12) , 2753
Asymptomatic Massive Choledocholithiasis in a Patient With Sickle Cell Disease and History of Remote Cholecystectomy
An abstract is unavailable. This article is available as a PDF only.
- 30 April 2025
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 120 (12) , 2753
Asymptomatic Massive Choledocholithiasis in a Patient With Sickle Cell Disease and History of Remote Cholecystectomy
An abstract is unavailable. This article is available as a PDF only.